What is Medrhythms?
Medrhythms is a pioneering digital therapeutics company dedicated to the development of next-generation neurotherapeutics designed to improve brain health and functional outcomes. At the heart of its technology platform is Rhythmic Auditory Stimulation (RAS), a sophisticated methodology that integrates music, sensors, and software to assist individuals suffering from neurologic injuries and walking disabilities. By providing personalized, evidence-based interventions, the company addresses the critical needs of patients living with conditions such as stroke and Parkinson's disease.
The firm's market position is defined by its unique ability to bridge the gap between clinical rehabilitation and accessible digital health solutions. By utilizing a culturally rich music library, Medrhythms offers a scalable, patient-centric approach to gait training, aiming to restore independence and enhance the quality of life for millions globally. This focus on functional recovery through digital innovation places the company at the forefront of the burgeoning neuro-rehabilitation sector.
How much funding has Medrhythms raised?
Medrhythms has raised a total of $35.6M across 3 funding rounds:
Series A
$5.3M
Series B
$27M
Private Equity
$3.3M
Series A (2018): $5.3M with participation from Peter J. Werth and Jean Hoffman
Series B (2021): $27M led by Morningside Venture Capital, Bose Ventures, Werth Family Investment Associates, Global Brain, and Advantage Capital
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in Medrhythms
Morningside Venture Capital
Morningside Venture Capital is a private equity and venture capital firm established in 1986 that specializes in early-stage technology company investments.
Global Brain
Global Brain is an independent venture capital firm that supports startups through hands-on assistance, strategic consulting, and a vast network across the technology and healthcare sectors.
Advantage Capital
Advantage Capital Partners is a venture capital firm that invests in diverse industries including life sciences, information technology, and energy.
What's next for Medrhythms?
With the successful closure of this major strategic investment, Medrhythms is well-positioned to scale its operations and expand its clinical footprint. The company's roadmap likely involves deepening its research into neurologic gait disorders while simultaneously broadening its therapeutic library to address a wider array of patient needs. As the firm moves into this enterprise-level phase, strategic partnerships with healthcare providers and large-scale clinical integration will be paramount to achieving widespread adoption.
Furthermore, the continued support from institutional investors suggests a focus on long-term sustainability and global market penetration. Medrhythms is expected to prioritize regulatory milestones and the expansion of its proprietary platform, ensuring that its digital therapeutics remain the gold standard for patients seeking to reclaim mobility through the power of rhythmic auditory intervention.
